Merck Co., Inc., WP97-A241, Sumneytown Pike, P.O. Box 4, West Point, PA 19486.
J Manag Care Spec Pharm. 2014 Sep;20(9):930-6. doi: 10.18553/jmcp.2014.20.9.930.
Community pharmacies are a convenient setting for vaccinating adults against infectious diseases in the United States. Whether the costs paid for vaccination in pharmacies differ from those in medical settings is unclear.
To examine whether the direct medical costs paid for adult vaccination differ by vaccination setting.
This was an observational retrospective study using 2010 MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases. Adults receiving herpes zoster or shingles vaccine, pneumococcal vaccine 23-valent, or influenza vaccines were identified using Current Procedural Terminology codes and National Drug Code numbers from medical and pharmacy claims files, respectively, between January 1 and December 31, 2010, in 1 of the following 3 settings: physician offices; other medical settings (e.g., inpatient/outpatient hospitals, emergency rooms); and pharmacies. Patients were adults aged ≥60 years on the date of zoster vaccination and aged ≥19 years on the date of pneumococcal or influenza vaccinations. The final study samples meeting inclusion/exclusion criteria were 54,042 for zoster vaccine, 154,994 for pneumococcal vaccine, and 1,657,264 for influenza vaccine. The vaccination costs included the health plan and enrollee paid amounts for the product; vaccine administration; dispensing fee; and, where applicable, the visit. The mean (SD) vaccination costs paid per vaccine administration were estimated by vaccine and type of setting, overall, and by geographic region and type of health plan. The costs paid for the same vaccine across vaccination settings were compared using analysis of variance with post hoc tests (Tukey).
Of those receiving zoster, pneumococcal, and influenza vaccines, 25%, 1%, and 7%, respectively, received the vaccines at a pharmacy. Compared with other U.S. regions, pharmacy-based vaccination for these 3 vaccines was generally more frequent in the West and the South. Overall, the mean (SD) costs paid per enrollee per vaccine administration at physician offices, other medical settings, and pharmacies were as follows: for zoster vaccine, $208.72 (42.10), $209.51 (50.83), and $168.50 (15.66), respectively (P <0.05); for pneumococcal vaccine, $65.69 (27.54), $72.11 (49.95), and $54.98 (9.72), respectively (P <0.05); and for influenza vaccine, $29.29 (15.29), $24.20 (13.12), and $21.57 (6.63), respectively (P <0.05). The mean amounts paid also differed by geographic region and type of health plan, with costs usually lower for the vaccinations given at pharmacies.
The average direct costs paid per adult vaccination were lower in pharmacies compared with physician offices and other medical settings by 16%-26% and 11%-20%, respectively. These results were mostly consistent across geographic regions and types of health plans. These data may help payers and policymakers understand the economic value of adult vaccination in different settings, especially in pharmacies.
在美国,社区药房是为成人接种传染病疫苗的便捷场所。但在药房接种疫苗的直接医疗费用是否与医疗场所不同尚不清楚。
检查成人疫苗接种的直接医疗费用是否因接种地点而异。
这是一项使用 2010 年 MarketScan 商业索赔和就诊记录以及医疗保险补充和协调福利数据库进行的观察性回顾性研究。通过医疗和药房索赔文件中的当前程序术语 (CPT) 代码和国家药品代码 (NDC) 号,分别于 2010 年 1 月 1 日至 12 月 31 日期间,在以下 3 种地点之一识别出接受带状疱疹或带状疱疹疫苗、23 价肺炎球菌疫苗或流感疫苗的成年人:医生办公室;其他医疗场所(如住院/门诊医院、急诊室);和药房。患者在带状疱疹疫苗接种日年龄≥60 岁,在肺炎球菌或流感疫苗接种日年龄≥19 岁。符合纳入/排除标准的最终研究样本分别为带状疱疹疫苗 54042 例、肺炎球菌疫苗 154994 例和流感疫苗 1657264 例。疫苗接种费用包括产品的健康计划和参保人支付金额、疫苗接种管理、配药费;以及,在适用的情况下,就诊费。根据疫苗和接种地点的不同,估计每次疫苗接种的平均(SD)接种费用,总体而言,并按地理位置和健康计划类型进行估计。使用方差分析和事后检验(图基)比较了在不同疫苗接种地点接种相同疫苗的费用。
在接受带状疱疹、肺炎球菌和流感疫苗的人群中,分别有 25%、1%和 7%在药房接种疫苗。与其他美国地区相比,西部和南部地区的这三种疫苗在药房接种的频率通常更高。总体而言,在医生办公室、其他医疗场所和药房为每位参保人每次接种的平均(SD)接种费用如下:带状疱疹疫苗为 208.72(42.10)美元、209.51(50.83)美元和 168.50(15.66)美元(P<0.05);肺炎球菌疫苗为 65.69(27.54)美元、72.11(49.95)美元和 54.98(9.72)美元(P<0.05);流感疫苗为 29.29(15.29)美元、24.20(13.12)美元和 21.57(6.63)美元(P<0.05)。平均支付金额也因地理位置和健康计划类型而异,药房接种的疫苗费用通常较低。
与医生办公室和其他医疗场所相比,成人每次接种的直接医疗费用在药房分别降低了 16%-26%和 11%-20%。这些结果在地理区域和健康计划类型方面基本一致。这些数据可能有助于支付方和政策制定者了解不同环境中成人疫苗接种的经济价值,尤其是在药房。